Soleno Therapeutics Faces Legal Scrutiny Following Patient Incident

Soleno Therapeutics finds itself navigating turbulent waters after reports emerged of a patient fatality connected to its lead drug candidate, VYCAKT XR. The situation has intensified with multiple prominent law firms announcing investigations into whether the biopharmaceutical company may have made misleading statements to its investors. This development raises critical questions about the company’s future trajectory and the commercial viability of its flagship treatment.

Market Reaction and Legal Response

The immediate catalyst for the current volatility was the disclosure involving a 17-year-old patient who passed away while undergoing treatment with VYCAKT XR. Soleno Therapeutics promptly issued a statement noting that the attending physician had found no causal link to the medication. Despite this clarification, investor sentiment soured dramatically, triggering a sharp sell-off that erased over 12% of the company’s share value in a single trading session on Wednesday.

This recent event has reignited concerns initially raised in mid-August by activist short seller Scorpion Capital. The firm published a controversial report expressing significant safety reservations about VYCAKT XR and suggesting the drug might eventually be withdrawn from the market. Building upon these earlier allegations, legal powerhouses Rosen Law Firm and Pomerantz LLP have now initiated formal probes. These investigations will focus specifically on whether Soleno provided adequate disclosure to the investment community regarding potential drug safety risks.

Analytical Perspective and Commercial Performance

Amid the prevailing uncertainty, several market experts maintain a more measured outlook. Some analysts have expressed surprise at the severity of the stock’s decline, pointing to the complex medical history and pre-existing conditions of the adolescent patient. Investment bank Stifel has reaffirmed its Buy recommendation for Soleno Therapeutics, maintaining a $118 price target. Piper Sandler remains even more optimistic, carrying a $145 target price.

Should investors sell immediately? Or is it worth buying Soleno Therapeut.?

These institutions base their confidence on two key factors. Firstly, patients diagnosed with Prader-Willi syndrome (PWS)—the condition VYCAKT XR is approved to treat—inherently face elevated risks for cardiovascular complications, including pulmonary embolism. Secondly, commercial adoption of the drug appears strong. As the first therapy approved specifically for addressing hyperphagia, or excessive hunger, in PWS patients, VYCAKT XR has demonstrated considerable market traction. The company reported net revenue of $32.7 million by the second quarter of 2025, stemming from 646 patients receiving treatment.

Navigating the Path Forward

The impending legal proceedings represent a significant overhang for Soleno’s stock price. The announcement of securities class action investigations typically introduces a prolonged period of uncertainty for shareholders, often spanning several months. Company leadership is scheduled to present at numerous investor conferences in the coming weeks, providing critical opportunities to address the allegations directly, clarify the safety profile of VYCAKT XR, and work to restore market confidence.

The central question facing investors and the company alike is whether this patient incident represents an isolated, tragic event or signals a broader, systemic safety issue that could ultimately undermine the commercial potential of VYCAKT XR. The answer will undoubtedly shape the future of Soleno Therapeutics and determine its ability to succeed in the competitive biotechnology landscape.